N

NRX Pharmaceuticals
D

NRXP

2.29000
USD
-0.16
(-6.53%)
مغلق
حجم التداول
3,300
الربح لكل سهم
-0
العائد الربحي
-
P/E
-1
حجم السوق
38,736,832
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AGIO
    1.430
    (4.23%)
    35.210 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    R
    RARE
    -1.920
    (-4.31%)
    42.590 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: NRX Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.